CRISPR Therapeutics AG (CRSP) Income from Continuing Operations (2015 - 2026)
CRISPR Therapeutics AG (CRSP) reported Income from Continuing Operations of 122931000.0 for Q1 2026, up 9.6% on a YoY basis from 112162381.98 in Q1 2025, and up 24.23% sequentially from 162245000.0 in Q4 2025.
CRISPR Therapeutics AG (CRSP) Income from Continuing Operations (2015 - 2026) Analysis & Trends
CRISPR Therapeutics AG (CRSP) has 12 years of Income from Continuing Operations data on file, last reported at 122931000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 9.6% year-over-year to 122931000.0; the trailing twelve-month figure through Mar 2026 stood at 600166000.0 (down 3391.11% YoY), and the FY2025 full-year result was 613211000.0, down 1728.93% from the prior year.
- Income from Continuing Operations advanced to 122931000.0 in Q1 2026, from 162245000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 366586000.0 in Q4 2024 to a low of 208549000.0 in Q2 2025.
- A 5-year average of 88366529.41 and a median of 116591000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations soared 310.09% in 2024 and sank 144.26% in 2025, its largest moves.
- Tracing CRSP's Income from Continuing Operations over 5 years: stood at 110575000.0 in 2022, then surged by 180.84% to 89392000.0 in 2023, then soared by 310.09% to 366586000.0 in 2024, then tumbled by 144.26% to 162245000.0 in 2025, then climbed by 24.23% to 122931000.0 in 2026.
- Business Quant data shows CRSP's Income from Continuing Operations at 122931000.0 in Q1 2026, 162245000.0 in Q4 2025, and 106441000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | CRISPR Therapeutics AG | 4.57 Bn | 2.12 Bn | - | -122.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -122.93 Mn |
| Dec 31, 2025 | -162.25 Mn |
| Sep 30, 2025 | -106.44 Mn |
| Jun 30, 2025 | -208.55 Mn |
| Mar 31, 2025 | -135.99 Mn |
| Dec 31, 2024 | 366.59 Mn |
| Sep 30, 2024 | -85.94 Mn |
| Jun 30, 2024 | -126.42 Mn |
| Mar 31, 2024 | -116.59 Mn |
| Dec 31, 2023 | 89.39 Mn |
| Sep 30, 2023 | -112.14 Mn |
| Jun 30, 2023 | -77.74 Mn |
| Mar 31, 2023 | -53.07 Mn |
| Dec 31, 2022 | -110.58 Mn |
| Sep 30, 2022 | -174.55 Mn |
| Jun 30, 2022 | -185.82 Mn |
| Mar 31, 2022 | -179.22 Mn |
| Dec 31, 2021 | -141.25 Mn |
| Sep 30, 2021 | -127.15 Mn |
| Jun 30, 2021 | 759.23 Mn |